semaglutide and cardiovascular outcomes in obesity The weight-loss drug Wegovy lowered heart attack risk a large trial Semaglutide and Cardiovascular Outcomes in
Description
Average weight loss ranges from 4 to 8 pounds cumulatively for people combining the dose with reasonable food and activity habits
Lancet Diabetes Endocrinol 13:221262 Secretariat EASO (2025) EASO response to the Lancet Commission Report on Obesity Diagnosis and Management
Using compounded semaglutide for weight management is off-label, as FDA-approved Wegovy is for this purpose
Duffy AM, Holscher C
Reported issues include dosing errors and quality/handling problems (FDA safety communication, updated 2025)
Extrapolation from related combination studies must be interpreted cautiously
